^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD16A agonist

    Related drugs:
    Apply
    Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203) (NCT05883449)
    Phase 2
    Affimed GmbH
    Recruiting
    Last update posted :
    05/27/2024
    Initiation :
    10/10/2023
    Primary completion :
    04/30/2026
    Completion :
    11/30/2027
    ALK • TNFRSF8
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    cyclophosphamide • fludarabine IV • acimtamig (AFM13) • AFM13/AB-101 • AlloNK (GCC4001)
    Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas (NCT04074746)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    04/18/2024
    Initiation :
    07/18/2020
    Primary completion :
    04/15/2025
    Completion :
    04/15/2025
    TNFRSF8
    |
    TNFRSF8 positive
    |
    cyclophosphamide • fludarabine IV • acimtamig (AFM13) • cyclophosphamide intravenous
    First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT05817058)
    Phase 1
    Affimed GmbH
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    03/21/2023
    Primary completion :
    03/01/2025
    Completion :
    03/01/2026
    IL3RA
    |
    CD123 positive • IL3RA positive
    |
    AFM28
    Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT) (NCT04101331)
    Phase 2
    Affimed GmbH
    Completed
    Last update posted :
    02/02/2024
    Initiation :
    11/13/2019
    Primary completion :
    05/11/2022
    Completion :
    01/11/2024
    TNFRSF8
    |
    TNFRSF8 positive
    |
    acimtamig (AFM13)
    Clinical Study of SM3321 With Solid Tumors (NCT06087770)
    Phase 1
    Beijing StarMab Biomed Technology Ltd
    Recruiting
    Last update posted :
    12/18/2023
    Initiation :
    12/07/2023
    Primary completion :
    08/19/2025
    Completion :
    10/14/2025
    CD4 • IL2
    Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers (NCT05109442)
    Phase 1/2
    Affimed GmbH
    Recruiting
    Last update posted :
    08/29/2023
    Initiation :
    11/19/2021
    Primary completion :
    09/30/2024
    Completion :
    06/30/2025
    EGFR
    |
    EGFR mutation • EGFR T790M • EGFR wild-type • EGFR positive
    |
    Tecentriq (atezolizumab) • AFM24
    Study to Assess AFM24 in Advanced Solid Cancers (NCT04259450)
    Phase 1/2
    Affimed GmbH
    Active, not recruiting
    Last update posted :
    08/23/2023
    Initiation :
    04/07/2020
    Primary completion :
    07/12/2023
    Completion :
    12/31/2024
    KRAS
    |
    KRAS wild-type • RAS wild-type
    |
    AFM24
    AFM13 in Relapsed/Refractory Cutaneous Lymphomas (NCT03192202)
    Phase 1/2
    Ahmed Sawas
    Completed
    Last update posted :
    07/20/2023
    Initiation :
    07/17/2017
    Primary completion :
    04/01/2020
    Completion :
    04/01/2020
    TNFRSF8
    |
    TNFRSF8 positive
    |
    acimtamig (AFM13)
    GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT02321592)
    Phase 2
    University of Cologne
    Completed
    Last update posted :
    11/13/2020
    Initiation :
    05/01/2015
    Primary completion :
    11/01/2019
    Completion :
    07/01/2020
    PD-L1
    |
    acimtamig (AFM13)
    Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE-206) (NCT02665650)
    Phase 1b
    Affimed GmbH
    Completed
    Last update posted :
    05/16/2019
    Initiation :
    05/01/2016
    Primary completion :
    01/01/2019
    Completion :
    03/01/2019
    TNFRSF8
    |
    Keytruda (pembrolizumab) • acimtamig (AFM13)